Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The combination DTaP-IPV/Hib vaccine was licensed in the United States in 2008 for children ages 6weeks through 4years with doses administered at 2, 4, 6, and 15-18months of age. The aim of this study was to assess the safety of DTaP-IPV/Hib vaccine routinely administered as part of clinical care to infants at Kaiser Permanente Northern California.
Methods: This was an observational, retrospective study that included all 2-month-old infants vaccinated with either DTaP-IPV/Hib or another DTaP-containing vaccine. We monitored all subjects for non-elective hospitalizations, emergency department visits and selected outpatient outcomes (seizures, Guillain-Barré Syndrome, encephalopathy, encephalitis, alteration of consciousness, meningitis, hypersensitivity reactions, immune thrombocytopenic purpura, hemolytic anemia, type 1 diabetes, and Kawasaki disease) beginning with their first dose through 6months after a 4th dose or until 24months of age. We calculated incidence rate ratios (IRRs) in the primary analysis by comparing rates of outcomes during the post-vaccination risk interval with rates during a comparison interval more remote from vaccination. Secondary analyses compared outcomes after DTaP-IPV/Hib with those after other DTaP-containing vaccines. We reviewed the medical records of selected outcomes.
Results: From October 1, 2008 through July 31, 2010, 14,042 subjects received a first dose of DTaP-IPV/Hib, 13,194 received 2 doses, 12,548 received 3 doses and 6702 received 4 doses. Overall, there were 166 comparisons with significantly elevated IRRs and 165 comparisons with significantly reduced IRRs. Medical record review of outcomes with significantly elevated IRRs in both the primary and secondary analyses did not suggest any relationship with DTaP-IPV/Hib.
Conclusions: This study did not detect any safety concerns following DTaP-IPV/Hib and provides reassurance that DTaP-IPV/Hib administered as part of routine care was not associated with unexpected safety risks. ClinicalTrials.gov Identifier: NCT00804284.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2016.06.062 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vaccination Status and Influencing Factors of Delayed Vaccination in Toddlers Born to Hepatitis B Surface Antigen-Positive Mothers.
Vaccines (Basel)
March 2025
Suzhou Center for Disease Control and Prevention, Suzhou 215000, China.
: This study aims to analyze the vaccination status and factors influencing delayed vaccination among toddlers born to hepatitis B surface antigen (HBsAg)-positive mothers. : Data of HBsAg-positive mothers between 1 January 2021 and 31 December 2022 were provided by the Suzhou Maternal and Child Health Care and Family Planning Service Center. The vaccination records were obtained from the Jiangsu Province Immunization Service Management Information System.
View Article and Find Full Text PDFImmunization coverage and timeliness of vaccination in young patients with inborn errors of metabolism: a French multicentric study.
Orphanet J Rare Dis
March 2025
Centre de référence Maladies Métaboliques ToTeM, Service de Médecine Pédiatrique, Hôpital Clocheville, CHRU Tours, 49 Bd Béranger, 37 044 Tours Cedex 1, Tours, France.
Background: Inborn errors of metabolism (IEMs) are rare disorders that are heterogeneous in severity and clinical presentation. Patients with IEMs should receive the vaccination schedule recommended for the whole population, and specific vaccinations, such as the seasonal influenza vaccine, for the most vulnerable. The aim of this study was to evaluate vaccination coverage and timeliness in young patients with an IEM.
View Article and Find Full Text PDFEffect of a proactive childhood vaccination reminder system on vaccination coverage and uptake in Denmark: A register-based cohort study.
Vaccine
April 2025
Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark. Electronic address:
Background: In August 2019, Denmark implemented a proactive childhood vaccination reminder system. This study aimed to assess the effect of the introduction of this vaccination reminder system on vaccination coverage and uptake of the first four childhood vaccinations, namely the tetanus, diphtheria, acellular pertussis, polio, haemophilus influenzae type b (Hib)-infection vaccination (DTaP-IPV/Hib) recommended at three, five and twelve months as well as mumps, measles, rubella vaccination (MMR1) recommended at 15 months.
Methods: This was a retrospective register-based cohort study based on two birth cohorts: children born in January 2018 (i.
The role of narratives in promoting vaccine confidence among Indigenous peoples in Canada, the United States, Australia, and New Zealand: a scoping review.
Int J Equity Health
March 2025
Human Sciences Division, Northern Ontario School of Medicine (NOSM) University, 935 Ramsey Lake Rd., Sudbury, ON, P3E 2C6, Canada.
Background: Many Indigenous youth and young adults in Canada, the United States, Australia, and New Zealand have reported low vaccine confidence, which has been linked to lower vaccination rates for COVID-19, MMR, HPV, DTaP-IPV-Hib, and pneumococcal conjugate vaccines. Narrative-based health promotion approaches, including those focused on strengthening vaccine confidence, have been used in public health interventions. Scoping reviews have become increasingly valued for their rigorous and reproducible exploration of evidence in public health research.
View Article and Find Full Text PDFReal-World Effectiveness of 3 Types of Acellular Pertussis Vaccines Among Children Aged 3 Months-16 Years in Lu'an, China: A Matched Case-Control Study.
Open Forum Infect Dis
February 2025
Public Health Department, Lu'an Hospital of Anhui Medical University, Lu'an, Anhui, China.
Background: The real-world vaccine effectiveness (VE) of the diphtheria, tetanus, and acellular pertussis (DTaP), DTaP- type b (Hib), and DTaP-inactivated polio (IPV)/Hib vaccines has not been thoroughly evaluated in China. Additionally, there are limited data on the VE of acellular pertussis-containing vaccines (aPVs) when used interchangeably.
Methods: We conducted a matched case-control study to estimate the VE of aPVs against polymerase chain reaction-confirmed pertussis infection in Lu'an in 2024.